Edition:
India

ChemoCentryx reports initial results from ongoing phase IB clinical trial of CCX872


Friday, 2 Sep 2016 

ChemoCentryx Inc : Reports initial results from ongoing phase IB clinical trial of CCX872 in patients with advanced pancreatic cancer . Expects to report progression-free survival (PFS) by end of 2016 . CCX872 was well tolerated by advanced pancreatic cancer patients. .Incidence and rate of adverse events were consistent with data reported historically for Folfirinox alone.